Cargando…
Role of ofatumumab in treatment of chronic lymphocytic leukemia
The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal antibodies to the treatment armamentarium. Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved in the US and Europe for the treatment of CLL r...
Autores principales: | Veliz, Marays, Pinilla-Ibarz, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262343/ https://www.ncbi.nlm.nih.gov/pubmed/22287865 http://dx.doi.org/10.2147/JBM.S13063 |
Ejemplares similares
-
The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011) -
The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
por: Castillo, Jorge, et al.
Publicado: (2010) -
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016) -
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
por: AlDallal, Salma M
Publicado: (2017) -
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
por: Gamal, Wael, et al.
Publicado: (2022)